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METHOD OF INHIBITING BINDING
ACTIVITY OF IMMUNOGLOBULINS

including mammalian immunoglobulins and particularly
IgA, IgG and IgM. This is accomplished through the utili
Zation of corresponding immunoglobulins hydrolyZed With

This is a continuation-in-part of US. patent application
Ser. No. 08/250,245 noW abandoned, ?led May 27, 1994.

plant proteases to provide peptides having a molecular
Weight of less than 10,000 Daltons and preferably of about
1,000 Daltons.
Additional objects, advantages and other novel features of

TECHNICAL FIELD

The present invention relates generally to the ?eld of
biotechnology and, particularly, to a method for inhibiting

the binding activity of immunoglobulins With immunogens,

10

a method for inhibiting culture agglutination and the actual
inhibitors.
BACKGROUND OF THE INVENTION

Many forms of immune proteins eXist in mammals includ
ing humans, and other classes of animals having immune
systems. It is generally believed that the immune proteins
IgM and IgG are the most important proteins that provide
protection against microbial invasion of mammals. IgM is
similar to IgG but is composed of ?ve IgG-like molecules in
a pentamer arrangement. The immunoglobulins IgM and
IgG are circulated in the blood to combat invasion by foreign

the invention Will be set forth in part in the description that
folloWs and in part Will become apparent to those skilled in
the art upon examination of the folloWing or may be learned
With the practice of the invention. The objects and advan
tages of the invention may be realiZed and obtained by
means of the instrumentalities and combinations particularly

pointed out in the appended claims.
15

To achieve the foregoing and other objects, and in accor
dance With the purposes of the present invention as

described herein, an improved method is provided for inhib

iting the binding activity of immunoglobulins With immu
nogens. The method is particularly adapted for utiliZation in
20

inhibiting the binding activity of mammalian immunogens
including, speci?cally, IgA, IgG and IgM immune proteins.
The method broadly includes the initial step of treating a

matter, mainly bacteria and are transferred to milk to estab

source of immunoglobulins With an enZyme that hydroliZes

lish immunity in nursing offspring.

the immunoglobulins into immunoreactive peptides having

Scienti?c literature suggests that the immune proteins
IgM and IgG interact When a binding site on the variable

25

a molecular Weight of less than 10,000 Daltons. Preferably,
the enZyme is a plant protease that cleaves the

immunoglobulins, IgA, IgG and IgM, above the second

regions of the light and heavy chains (see FIG. 1) attaches
to an antigenic site or to a complimentary binding site on the

disul?de bond (see FIG. 1). This results in the liberation of

tail of the heavy chain (Fc fraction) of another IgM or IgG
molecule. Many researchers believe that IgM and IgG lose

tWo Fab fractions. The enZymes papain, ?cin and bromelain
are particularly useful for this purpose.

their interactive ability When the heavy chains are removed
from the Fab fractions. Our Work in the development of the

above the second disul?de bond, the hydrolysis is continued

In addition to cleaving the immunogens IgA, IgG and IgM

present invention, hoWever, indicates that the carbohydrate
moieties or constant regions on both the light and heavy

chains of immune proteins are capable of interacting With

for an additional period of time to clip and remove the
35

antigenic sites and/or bridging compounds thereby causing
immune reactions and agglutination. Thus, it should be
appreciated, that simple cleavage of the Fab fraction is not
effective to inhibit immune reactions. Accordingly, a neW

method must be developed to achieve this end.

plished through ultra?ltering the source of immunoglobulins
40

SUMMARY OF THE INVENTION

as they are hydroliZed With the enZyme. A dia?ltration
technique may be utiliZed so that the smaller peptide frac
tions produced as a result of hydrolysis (i.e. those under
10,000 Daltons) pass as permeate through a polysulfone or
other membrane having a molecular Weight cut off of 10,000

Daltons. Speci?cally, to achieve this end, hydrolysis pref

Accordingly, it is a primary object of the present invention
to provide a method for inhibiting the binding activity of

erably is completed at a temperature betWeen 30—50° C. for
a period of at least tWo hours. As permeate is removed from
the source of immunoglobulins undergoing hydrolysis a
buffer of equivalent volume may be added.
The permeate, consisting of peptides of a molecular

immunoglobulins With immunogens. Such a method has a

number of bene?cial applications including, but not limited
to, inhibiting culture agglutination in a fermentation medium
and blocking selected antigenic sites so as to prevent prob
lematic immune reactions in the health care ?eld.

carbohydrate moiety or constant regions from the variable
regions so as to provide a peptide fraction having a molecu
lar Weight of less than 10,000 Daltons. This may be accom

50

Yet another object of the present invention is to provide a
method for inhibiting culture agglutination in a fermentation

Weight of less than 10,000 Daltons and preferably approxi
mately 1,000 Daltons is then collected. FolloWing collecting
is the reacting of immunogens With the peptides so as to bind
and block antigenic sites on the immunogens. Then folloWs

medium Wherein agglutination of the microorganisms
responsible for fermentation is substantially prevented. Such

(eg cheddar cheese, cottage cheese).

the introducing of the peptide bound and blocked immuno
gens into the mammal. Advantageously, the bound and
blocked antigenic sites on the immunogens make the immu
nogens substantially “invisible” to the immune system of the

Still another object of the present invention is to provide
a method for inhibiting the binding activity of mammalian
immunoglobulins and in particular IgA, IgG and IgM in a

immune reactions from occurring.
Such an approach has a number of applications including,

a method alloWs, for example, more ef?cient production of
a more consistent and higher quality fermentation product

55

mammal thereby preventing undesired and problematic
60

biologically safe and effective manner. Such an approach
may be utiliZed to limit or prevent immune reactions and
prevent infection and, accordingly, are bene?cial for a
number of uses in the care and treatment of patients suffering
from a number maladies.

Yet another object of the present invention is to provide

inhibitors of the binding activity of immunoglobulins

speci?c use in the arti?cial insemination of mammals

including humans and other animals. Speci?cally, the sperm
cells to be inseminated are reacted With the peptide so as to
65

bind and block the antigenic sites or determinants on the
sperm cells. When subsequently inseminated into a

recipient, the immune reaction of the recipient is reduced

and/or substantially eliminated, and accordingly, the aggre

US 6,348,346 B1
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gation of sperm cells is virtually prevented. Thus, the sperm

Still other objects of the present invention Will become
apparent to those skilled in this art from the folloWing
description Wherein there is shoWn and described a preferred
embodiment of this invention, simply by Way of illustration

cells remain free to reach the ovum for purposes of fertili
Zation.
In accordance With yet another aspect of the present
invention, a method for inhibiting culture agglutination in a

of one of the modes best suited to carry out the invention. As

it Will be realiZed, the invention is capable of other different

fermentation medium including immunogens is provided.
As before, this method includes an initial step of treating a

embodiments and its several details are capable of modi?

source of immunoglobulins With an enZyme such as a plant

cation in various, obvious aspects all Without departing from

the invention. Accordingly, the draWings and descriptions

protease to hydroliZe the immunoglobulins into peptides
having a molecular Weight of less than 10,000 Daltons and

10

tive.

preferably, approximately 1,000 Daltons. Speci?cally, as
previously described these peptides are produced utiliZing
ultra?ltration and dia?ltration techniques. Preferably,
papain, ?cin and/or bromelain is used as the enZyme.
The immunoglobulins may be obtained from a number of
sources including, but not limited to, raW Whey, dry Whey,

Will be regarded as illustrative in nature and not as restric

BRIEF DESCRIPTION OF THE DRAWING

The accompanying draWing incorporated in and forming
15

a part of this speci?cation, illustrates several aspects of the
present invention, and together With the description serves to

Whey protein isolates, non-fat-dried milk, blood serum pro

explain the principles of the invention. In the draWing:

tein isolates, puri?ed immunogen preparations and mixtures

FIG. 1 is a schematical representation of an IgG molecule;
FIG. 2 graphically shoWs the rate of top and bottom pH
decrease of OS culture;
FIG. 3 graphically shoWs the rate of top and bottom pH
decrease of M30 culture;
FIG. 4 graphically shoWs the rate of top and bottom pH
decrease of M37 culture;
FIG. 5 is a plot of the pH at the top of the skim milk

thereof.

FolloWing hydrolysis is the collecting of the peptides

20

produced as a result of the treatment of the immunoglobulins

With papain, ?cin and/or bromelain and in accordance With

the ultra?ltration and dia?ltration techniques. Speci?cally,
the resulting peptides present in the permeate may be
concentrated utiliZing reverse osmosis or evaporation and
then dried using freeZe drying, spray drying or vacuum

25

column after addition of immunoglobulin (IgG), ?cin
derived peptides, papain derived peptides and bromelain
derived peptides per example 8; and

drying techniques. These dried preparations can then be
formulated into existing culture media preparations.
The peptides in these culture media preparations are then

utiliZed by inoculating a groWth media for microorganisms,
useful in fermenting the fermentation medium, With the
peptides. Next is the groWing of the microorganisms in the
inoculated groWth media Whereby the peptides bind anti
genic sites on the microorganisms. This is then folloWed by
adding the microorganisms groWn in the inoculated groWth
media to the fermentation medium Whereby the peptide

30

Reference Will noW be made in detail to the present
35

microorganisms.

40

throughout the milk and uneven acid production in the
cheese vat. Grainy, shattered curd, sediment formation and
sloW acid production are all problems that directly relate to
agglutination of lactic acid starter strains. Accordingly,
direct consequences of agglutination are inconsistent prod
uct quality and yield losses Which both lead to decreased
pro?ts. Accordingly, as the present invention addresses and

treating mammalian immunoglobulins including IgA, IgG
45

blood serum protein isolates, pure fat immune protein prepa
rations and mixtures thereof. It should be appreciated,
hoWever, that this list is not exclusive and that other sources
of immunoglobulins can be utiliZed.

55

invention, an inhibitor is provided for inhibiting the binding

activity of immunoglobulins and particularly mammalian

Preferably, the enZyme utiliZed cleaves the IgA, IgG and
the IgM above the second disul?de bond (see FIG. 1).
Accordingly, plant proteases such as papain, ?cin and bro
melain are particularly useful enZymes for purposes of the
method of the present invention. Other enZymes such as

immunoglobulins including IgA, IgG and IgM. Speci?cally,
the inhibitor is derived from a source of immunoglobulins

hydroliZed With a plant protease such as papain, ?cin and/or

and IgM With an enZyme that hydroliZes the immunoglo
bulins into immunoreactive peptides having a molecular
Weight of less than 10,000 Daltons. Any source of immu
noglobulins may be utiliZed including, for example, raW

Whey, dry Whey, Whey protein isolates, non-fat-dried milk,
50

largely relieves the agglutination problem, it represents a
signi?cant advance in the art.
In accordance With still another aspect of the present

A method for inhibiting the binding activity of immuno

globulins and, particularly mammalian immunoglobulins
IgA, IgM and IgG With an immunogen Will noW be
described in detail. The method includes the initial step of

Such a method is particularly useful in the production of
cottage, cheddar and other cheeses Wherein agglutination is
a signi?cant problem leading to revenue loss. Speci?cally,
agglutination results in uneven distribution of starter culture

preferred embodiment of the invention, an example of Which
is illustrated in the accompanying draWing.
DETAILED DESCRIPTION OF THE
INVENTION

bound antigenic sites on the microorganisms block the

immunoglobulins in the fermentation medium from binding
those antigenic sites and thereby causing agglutination of the

FIG. 6 graphically shoWs free sWimming sperm cells in
control and papain derived peptide treated spermatoZoa
samples per Example 10.

60

trypsin, chymotrypsin and pepsin fail to provide the desired
cleavage above the second disul?de bond and, accordingly,
are not appropriate for utiliZation in the present method.

bromelain and then ultra?ltered With or Without dia?ltering

to provide peptides having a molecular Weight of less than

More particularly, the production of the desired peptides

10,000 Daltons and preferably approximately 1,000 Daltons.

is completed in accordance With ultra?ltering With or With
out dia?ltering techniques. Preferably, the source of immu
noglobulins being treated With the enZyme is ultra?ltered
through a polysulfone or other membrane having a molecu

Such an inhibitor Will have a number of unique biotechno
logical applications such as in the health care ?eld Where it
is particularly desirable to block problematic immune reac
tions.

65

lar Weight cutoff of 10,000 Daltons. The permeate, that is,

US 6,348,346 B1
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the material passing through the membrane, comprises pep

erWise prevent a medical doctor or technician from com

tides having a molecular Weight of less than 10,000 Daltons.
Included in this are the carbohydrate moieties clipped from

pleting treatment and achieving a desired result. For
example, in the instance of arti?cial insemination, a greater
number of spermatoZoa are maintained viable through inhi

the light chains and variable regions of the IgA, IgG and IgM
molecules. In fact, peptides having a molecular Weight of
slightly greater than 1,000 Daltons have been found to
provide the greatest inhibitory activity relative to the binding
of immunoglobulins With antigen sites. Peptides smaller
than 1,000 Daltons generally exhibit less activity and,
therefore, are of little interest relative to the present method.

bition of the binding activity of the immunoglobulins of the
female host. Accordingly, these spermatoZoa remain free to
reach the ovum and complete the desired fertiliZation.

10

As the peptide permeate is collected, an appropriate buffer
(e.g. pasteuriZed skim milk) may be added to the source of
immunoglobulins being treated With the enZyme. This is

step of treating a source of immunoglobulins With an

enZyme (e. g. papain, ?cin and/or bromelain) to hydroliZe the
immunoglobulins into peptides having a molecular Weight

done volume-for-volume so that the original volume of the

immunoglobulin source and enZyme (i.e. the retentate) is

In accordance With yet another aspect of the present
invention a method is provided for inhibiting culture agglu
tination in a fermentation medium including immunoglobu
lins. As previously described, the method includes the initial

15

of less than 10,000 Daltons. The ultra?ltration and dia?l
tration techniques already described are utiliZed for this

substantially maintained at a given level.
The enZymatic treatment of the immunoglobulins is com

purpose. Similarly, the collecting of the peptides and the

pleted at any temperature Where enZymatic inactivation does
not occur. HoWever, temperatures just beloW the enZyme’s

formulation into culture media preparations is also com

point of denaturation are most ef?cient. Accordingly, for
papain, ?cin and bromelain the enZymatic treatment is

concentrating and drying of the peptides for subsequent
20

pleted. These peptides, preferably, of approximately 1,000
Daltons and incorporating carbohydrate moieties clipped
from tips of the light chains or variable regions of IgA, IgG
and IgM immune proteins function to inhibit the binding

completed betWeen 30—50° C. and most preferably approxi
mately 40° C. Further, the enZymatic treatment is completed

activity of immunoglobulins.

for a relatively extended period of time of at least tWo hours.
25

the immune proteins IgA, IgG and IgM including the

The next step in the method of inhibiting culture agglu
tination is the adding of the peptides to a groWth media for

constant regions and carbohydrate moieties of the variable
regions and light chains. Of course, as the small peptides are
cleaved, they are Washed through the ultra?ltration mem

medium. Speci?cally, the peptides are mixed With the
groWth media at a Weight ratio of peptides to microorgan

This alloWs the enZyme to hydroliZe signi?cant portions of

brane as permeate.

microorganisms useful in fermenting the fermentation
30

As indicated above, the permeate from the ultra?ltration

comprises peptides of less than 10,000 Daltons and

preferably, peptides of approximately 1,000 Daltons. Fol
loWing collection, these may be concentrated utiliZing
reverse osmosis or evaporation in accordance With proce

35

dures Well knoWn in the art. These peptides may then be

dried by using freeZe drying, spray drying, or vacuum drying

groWth media, the peptides bind to antigenic sites or deter
40

directly or recovered as, for example, by means of centrifu
gation in a manner knoWn in the art. Next is the adding of

inhibiting the binding activity of mammalian
45

50

and blocked antigenic sites prevent immunoglobulins in the
fermentation medium (e.g. Whey or milk culture) from
binding With the microorganisms and agglutinating micro
organisms to form long chains or clumps that entrap acid

agglutination is signi?cantly reduced and/or substantially

maintain the viability of the spermatoZoa. The inhibitory

may be suitably mixed by agitation for a period of approxi
mately 15 minutes.
FolloWing the reacting of the immunogen With the pep
tides is the step of introducing the peptide bound and
blocked immunogen (e.g. spermatoZoa) into the mammal.

the microorganisms groWn in the inoculated groWth media
to the fermentation medium. There the microorganisms
remain free to promote fermentation. Speci?cally, bound

coagulated casein and settle to the bottom of the vat.
As a result of the method of the present invention,

appropriate quantity of physiologically balanced sodium
citrate solution maintained at an appropriate temperature to

peptides are then added to the spermatoZoa solution Which

minants on the microorganisms.

FolloWing groWth, the microorganisms may be used

In accordance With further aspects of the method for

immunoglobulins, the next step is the reacting of an immu
nogen With the peptides produced and collected in the
manner just described. These peptides then bind and block
antigenic sites/determinants on the immunogens. This may
be done in accordance With any number of Ways appropriate
to achieve this purpose. For example, Where spermatoZoa
are being treated for purposes of subsequent arti?cial
insemination, the spermatoZoa may be diluted by adding an

lated groWth media for a period of time of generally betWeen
3 and 24 hours While maintaining the growth media Within
a temperature range necessary to promote groWth and main
tain the viability of the microorganisms. Preferably, some
mixing is provided, such as With internal pH controlled
groWth media through, for example, sloW agitation or other
means. As the microorganisms groW in the inoculated

techniques also Well knoWn to those skilled in the art. These

dried preparations may then be subsequently formulated into
usable preparations for any number of applications.

isms of at least substantially betWeen 0.05 to 1 and 0.2 to 1.
Microorganisms are then added to and groWn in the inocu

55

eliminated. This results in an improved and more consistent

distribution of microorganisms or starter culture throughout
the fermentation medium and a more even acid production

in the vat. Accordingly, product quality is more consistent
and yield losses are reduced to the economic bene?t of the
manufacturer.
60

Since the antigenic sites are bound and blocked, the natural

The folloWing example is presented to further illustrate

antibody defense netWork of the mammal is essentially

the invention, but it is not to be considered as limited to.

prevented from reacting and attacking the immunogen.

EXAMPLE 1
Cultures:
Frozen commercial Lactococcus lactis bulk starter cul

Accordingly, problematic immune reactions may be essen

tially defeated. Thus, it should be appreciated that this
invention has potentially unlimited applications in the health
care ?eld Where problematic immune reactions might oth

65

tures OS, M30 and M37 (Rhone-Poulenc/Marschall Div.,
Madison, Wis.) Were inoculated (0.1 g) into 10 mL aliquot

US 6,348,346 B1
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8

of reconstituted NFDM (10% Wt/vol) Which had been ster

linear model procedure of Statistical Analysis System to

ilized. The tubes Were incubated at 26° C. for approximately

determine differences betWeen media on agglutination.

3 hours or until a curd Was formed. In the second propaga

Least squares means and signi?cance of each treatment Were

tion the formed curd Was transferred into 100 mL of steril

computed using Type IV sums of squares and predicted
difference procedure. Least signi?cant differences Were
computed for top and bottom pH differential. A pH differ

ized NFDM (10% Wt/vol) and incubated for 18 hours. 10
milliliters of the second propagation Was transferred into
enzyme treated and control media, prepared as described
beloW and incubated.
Commercial cultures OS, M30 and M37 Were selected
because of their sensitivities to agglutination. The OS cul
ture is a cottage cheese culture Which does not normally

ential betWeen top and bottom pH of 0.12 units or greater
Was signi?cant (P<0.05). This pH differential Was used as an
10

SloW or uneven acid production has been reported as an

indicator of culture agglutination in previous studies. In this

agglutinate. This culture Was used as a control in the

study acid production Was also used as an indicator of

experimental design. Cultures M30 and M37 are cheddar
cheese cultures that are extremely sensitive to agglutination.
These tWo cultures represent a Worst case scenario if used in 15

the manufacture of cottage cheese.

Media Preparation:
Rennet Whey Was treated With papain (Sigma Chemical
Co., St. Louis, Mo.) While being ultra?ltered and dia?ltered
using a holloW ?ber membrane (Supelco, Bellefonte, Pa.)

indicator of starter culture agglutination.
Culture Performance:

agglutination, thus an indicator of culture performance.
Culture performance over the 5 hour incubation period in
skim milk improved (P<0.01) for all three commercial
cultures studied (OS, M30 and M37) When groWn in enzy

mically treated Whey medium compared to the control

(untreated Whey) medium (Table 1).
20

TABLE 1

With a molecular Weight cut-off of 10,000 Daltons. The
process ran for 2 hours at 40° C. The permeate Was collected

Effect of enzymically treated Whey internal

and freeze dried. The freeze dried permeate Was added (at

pH control media on rate of acid development
in skim milk.

41.7% level, dry Weight basis) to an internal pH control
buffer salt mixture (as described in US. Pat. No. 4,402,986)

25

Culture

(GalloWay West, Wis.) to replace the Whey. Acontrol media
Was prepared using untreated Whey. Both media Were recon

Media

stituted (75.7 g/L) split into three fractions and heat treated

OS

M30

M37

5.251
5.26

6.23
5.40

6.22
5.81

Top pH

1.
2.

Control
Enzyme

Bottom

1.

treated
Control

5.10

5.55

5.57

Monitoring Agglutination:

pH

2.

Enzyme

5.17

5.08

5.63

Culture agglutination Was monitored by determining the
pH differential in skim milk and by direct microscopic

pH
diff.2

1.
2.

0.15
0.09

0.68
0.31

0.64
0.18

at 85° C. for 45 minutes. The media Were cooled to 26° C.
and inoculated With the test cultures and incubated at 26° C.
for 16 hours or until pH 5.3 Was achieved.

examination. Agglutination in skim milk Was monitored by
inoculating the fermented media at a 5% level into pasteur

30

treated
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1Least square means. Reps = 4 for all treatments, n = 20. A least square
difference of 0.12 Was calculated When P = 0.05.

ized (63° C., 30 minutes) skim milk contained in 1000 mL
graduated cylinders and incubated at 32° C. The pH differ
ential Was determined by measuring top and bottom pH of
skim milk in the graduated cylinders at 1 hour intervals over
5 hours. Recordings Were made 5 centimeters beloW the
skim milk surface and at the bottom of the cylinder. A pH

meter (American Scienti?c Products, McGaW Park, Ill.) Was
equipped With an Orion combination pH electrode (Orion
Research, Inc., Boston, Mass.). The electrode Was attached

2pH differential = top pH — bottom pH

1Least square means. Reps=4 for all treatments, n=20. A least square

40 difference of 0.12 Was calculated When P=0.05.

2pH differential=top pH-bottom pH.
The OS culture, Which is a mixed strain culture that

45

to a stainless steel rod, Which Was used to loWer the electrode
to the bottom of the cylinder. A pH differential Was com

puted by subtracting bottom pH from the top pH.
At the end of 5 hours of incubation the bottom of the

graduated cylinders Were visually inspected for sediment

50

formation. Differences in total solids betWeen top and bot

infrequently agglutinates in agglutinin rich milk or under
normal conditions, shoWed the least (P<0.01) amount of
culture agglutination When groWn in the media. These
results Were expected. The OS culture during the 5 hours of
incubation had a faster rate of acid development (decrease in
pH) (P<0.01) (see FIG. 2 and Table 1) and a smaller pH
differential (P<0.01) (Table 1) than M30 and M37 cultures
(see also FIGS. 3 and 4 and Table 1). Skim milk inoculated
With OS culture groWn in control or enzymically treated
media and incubated had a similar rate of acid production

tom of the cottage cheese vats is a sensitive indicator of

agglutination. Milk (or curd) samples Were taken from the

(rate of pH decrease) at the top and bottom of the graduated
cylinders. The pH decreased steadily up to 4 hours of

bottom of the cylinders and stored at 4° C. overnight for

direct microscopic examination the folloWing day. Next day

Control
Enzyme
treated

55

samples Were gram stained in accordance With the procedure
described in Wu, W. G. Ed. 1986. Stains and Media. Page 33,

incubation and leveled off at pH 4.5 When the skim milk

coagulated (FIG. 2). HoWever, over the 5 hour incubation
period the pH differentials Were loWer for culture incubation

Medical Microbiology: ALaboratory Study. Star Publication

enzymatically treated Whey medium suggesting that the

Company, Bellemont Calif., in order to determine culture
groWth characteristics and cells per chain distribution by

performance of the OS culture Was improved by 40%. The
60

pH differentials Were 0.15 and 0.09 for enzyme treated and

microscopic examination. Photomicrographs (1000><) Were

control media, respectively (Table 1). When the skim milk

prepared to illustrate the differences in culture groWth
characteristics, the extent of chain formation and clumping

cylinders Were visually inspected at the end of 5 hours, no
visual sedimentation Was observed in either cylinder.
When commercial M30 culture Was groWn in enzymically
treated Whey medium and inoculated into skim milk con

betWeen the cultures groWn in the tWo media.

Statistical Analysis:
The experiment Was replicated four times in a randomized

complete block design. Data Was analyzed using the general

65

tained in graduated cylinders, rate of acid production at the
top of the cylinder improved (P<0.01) over the 5 hour

US 6,348,346 B1
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incubation period compared to the same culture grown in the

no clumps and shorter chains appear more evenly dispersed

control medium (see FIG. 3 and Table 1). In the cylinders

throughout the skim milk. Photomicrographs of the three
cultures groWn in the control medium and enZymically
treated Whey medium shoWed that all three cultures formed
considerable shorter chains and almost no clumping of
chains When these cultures Were groWn in enZymically
treated Whey medium compared to their controls.

inoculated With the M30 culture groWn in control media, top

pH decreased only by 0.08 pH units over 5 hour period. This
culture agglutinated Within the ?rst hour of incubation
sinking to the bottom of the cylinders. Acid production at the
bottom of the cylinders Was rapid as observed by rapid

decline in bottom pH of the cylinders (FIG. 3).
When the M30 culture Was groWn in the enZymically
treated media and inoculated into skim milk, pH both at the
top and at the bottom of the cylinders decreased at the same
rate. The pH differential over 5 hour incubation period Was

Short chains lacking in critical mass to sink to the bottom

of the cylinders are more evenly dispersed throughout the
10

acid production particularly at the top of the cylinders Was
observed.

reduced from 0.68 (cultures groWn in the control medium)

to 0.31 (that groWn in enZymically treated medium) (Table
1). The pH differential Was decreased (P<0.01) by 55%
suggesting that culture agglutination Was being inhibited
and culture performance improved.
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EXAMPLE 3

When groWn in the enZyme treated Whey media compare to
the control (Table 1 and FIG. 4). When M37 Was groWn in
the control medium and inoculated into skim milk, the rate
of acid production at the top of the cylinder Was sloW. The
pH decreased by 0.06 units over 5 hours. Similar to the M30

20

culture, M37 also agglutinated Within the ?rst hour of
incubation falling to the bottom of the cylinders. The pH
decrease at the bottom of the cylinders Was fairly rapid

25

The procedure set forth in Example 1 is folloWed except
that ?cin is substituted for papain.
EXAMPLE 4

during the 5 hours of incubation (see FIG. 4).
30

The procedure set forth in Example 1 is folloWed except
that bromelain is substituted for papain.
EXAMPLE 6

0.64 for cultures groWn in the control medium to 0.18 to that

differential Was reduced (P<0.01) by 72% suggesting an
inhibition of culture agglutination and improvement of cul
ture performance.
The cylinders Were visually inspected at the end of the 5
hours for sediment formation. Cylinders inoculated With

The procedure set forth in Example 1 is folloWed except
that raW Whey is substituted for rennet Whey.
EXAMPLE 5

the cylinders over the 5 hours (see FIG. 4). The pH differ
entials over the 5 hour incubation period decreased from

groWn in enZymically treated medium (Table 1). The pH

EXAMPLE 2

The procedure set forth in Example 1 is folloWed except
that non-fat dried milk is substituted for rennet Whey.

Among all three commercial cultures studied, M37
shoWed the greatest improvement: in culture performance

When the M37 culture Was groWn in the enZymically
treated media and inoculated into skim milk a steady
decrease in pH Was observed at the top and at the bottom of

skim milk providing for improved culture performance
throughout the cylinder during incubation. Thus improved

35

The procedure set forth in Example 1 is folloWed except
that non-fat-dried milk is substituted for rennet Whey and
?cin is substituted for papain.
EXAMPLE 7

40

M30 and M37 cultures groWn in the control medium both

The procedure set forth in Example 1 is folloWed except
that raW Whey is substituted for rennet Whey and bromelain

is substituted for papain.

had heavy sedimentation (5 and 6 cm deep, respectively) at
the bottom of the cylinders. This sediment Was greatly

EXAMPLE 8
reduced When M30 and M37 cultures Were groWn in the
Lactococcus lactis ssp. lactis B62 (Chr. Hansen
enZyme treated medium. A slight broWn tint on the color of 45
Laboratories,
MilWaukee, Wis.) Was propagated from froZen
the sediment Was also observed indicating that little addi

tional casein from skim milk precipitated around the agglu
tinated cell complexes.
Statistical analysis shoWed media><culture interaction to
be signi?cant (P<0.01) for rate of decrease of top and bottom
pH and pH differentials. The extent that the culture perfor
mance is improved When groWn in the enZymically treated
Whey medium depends someWhat on the speci?c culture and
perhaps is related to the severity of agglutination associated
With a particular strain. The severity of agglutination of a

stock cultures in reconstituted (10%) nonfat dry milk. Insure

Media (Waterford, Food Products) Was prepared (75.8 g/L
distilled Water) and inoculated (4%) With the propagated
50

digested With crude Papain (1%), crude Ficin (0.1%) and
crude Bromelain (0.01%) at 26° C. for 2 h. Digested Beef
55

particular strain depends on several factors such as the

frequency that a speci?c antigenic determinant is expressed
60

medium sold by Waterford Food Products Which supplied
both an intact medium (InsureTM) and the buffering salts
(InsureTM salts) used in their intact medium. TWo media
Were prepared from InsureTM medium, one of Which Would

investigated.

be used in a treatment spiked With puri?ed immunoglobulin
(1 g/250 mL). These tWo media Were used as controls. Three

Culture Morphology:
When Lactococcus cultures agglutinate, long chains or
clumps of chains are observed in the sediment formed,
Whereas nonagglutinating cultures form smaller clumps or

Plasma Was ultra?ltered (3000 mWco, Dia?o Ultra?ltration
membranes, Amicon, Inc.) at 4° C. Permeates Were stored
(—10° C.) until media Were formulated.
Five Internal pH Controlled bulk starter media Were
prepared. Media Were designed around a commercial lactic

on the cell surface or the agglutinin titer Which may indicate
an antibody’s speci?city to a certain cell surface antigenic

determinant. Perhaps these factors contributed to the differ
ences observed in this study and the extent of improvement
in culture performance of the various commercial cultures

culture and incubated at 26° C. overnight.
Five hundred mL aliquots of Beef Plasma (4%) Were

65

media Were prepared using the InsureTM salts (0.15 g) plus
yeast extract (1%, amount normally in INSURETM medium)
reconstituted With 5 mL of one of three enZyme hydrolyZed

US 6,348,346 B1
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permeates. All media Were heat treated at 85° C. for 45 min
and stored at 4° C. A commercial single strain lactic culture
B62 Was used to inoculate (50%) these media. All Were

blood serum as shoWn in this example. Indeed any source of
material that contains immunoglobulin may be used as a

starting material to produces these peptides.

incubated (26 C) overnight to develop bulk starters.
Nonfat dry milk (8.8%) Was reconstituted in distilled

EXAMPLE 9

Water and placed in ?ve (250 mL) graduated glass cylinders.

The procedure set forth in claim 8 is folloWed except that
a puri?ed immune protein preparation is substituted for the

One g of freeze dried, puri?ed immunoglobulin protein Was
added to one skim milk-containing cylinder. Control culture
Was added to the cylinder containing the immunoglobulin.
The other skim milk containing cylinders Were inoculated
With the other bulk starters. All skim milks Were inoculated
With 4% bulk starter. All skim milk-cylinders Were incu
bated at 31° C. for 6 h. pH measurements Were determined
after inoculation and at 1 h intervals. pH measurements Were
taken at 5 cm beloW the surface and on the bottom of each

cylinder.

digested beef plasma.
10

Often Women can not become pregnant because their

immune system (immuno-proteins IgM, IgG and IgA)
15

A plot of the pH at the top of the skim milk column is
shoWn in FIG. 5. As expected the skim milk containing the
added immunoglobulin had the sloWest drop in pH. This is
because the immunoglobulin enhances culture
agglutination, that causes the cells to clump together and fall

the sperm surface a conformation shift occurs alloWing

complimentary binding to occur, thus chains of immune
20

thus they are unable to travel far enough to ?nd and fertiliZe
the female egg. The purpose of this project Was to ?nd a Way

to inhibit spermatoZoa agglutination.

on the bottom of the cylinder the acid development in the top
of the skim milk column Was limited to the culture remain

25
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collected peptides.
Preparation of blood serum. Bovine blood Was collected
at the time of slaughter. The blood Was alloWed to coagulate
While cooling to 2° C. Coagulated blood Was stirred and
centrifuged at 5000><g for 10 min. Serum from each centri
fuge tube Was carefully removed and stored in 1 and 2 ml
cryo-vials. Cryovials Were froZen at —20° C. until the serum

controls. Also note that the bulk starters that contained the

Was used.
40

and resuspended in TEST buffer to their original volume. A
reaction mixture Was prepared from 5 ml of Washed

be the most protected. The pH of this skim milk dropped

peptides.

spermatoZoa, With and Without 10 mg peptide blockers, and
45 either 0.4 or 0.5 ml Bovine blood serum. SpermatoZoa Were

monitored at 0,1, 5, 10, 15, 20, 25, 30 min. to determine the
number of active cells, motility, and grade.
Agglutination determination. SpermatoZoa from reaction
mixtures Were placed (0.05 ml) on a Warmed (38° C.) slide

The pH differentials (difference betWeen the top and
bottom pH of the skim milk after four hours of incubation)
is shoWn in Table 2. Differentials result When culture cells
drop to the bottom of the cylinder. The lactic cells on the
bottom are more numerous and therefore produce more acid

50 and covered With a cover slip. The slide Was placed an a

Warmed microscope table (38° C.) and vieWed at 100><.
Slides (Ektachrome 5017, ASA 100) Were taken at all

than those throughout the body of the skim milk. Note that
the cultures groWn in the media containing peptides had a
loWer differential than the controls.

observations times.
Total sperm cell numbers Were determined using direct
55

TABLE 2
Effect of culture media on pH differentials
in skim milk after 4 h of incubation.

pH differential
.51
.56
.46

Insure salt + Papain peptide

.32

Insure salt + Bromelain peptide

.37

60

protective blockers can be cut from milk sources or from

microscopic observation techniques using a calibrated slide.
Number of free cells Were determined from the slides by
counting the free sperm cells that Were not in clumps. Total
free sperm cell counts /ml Were then computed from the area
ratio of the calibration slide.
Mobility Was determined by a trained technician Who
estimated the number of spermatoZoa that Were actually
moving using a scale of 0 to 100. Grade of spermatoZoa

(hoW Well they move) Was also determined by the same
65

It is evident from Examples 1—7 that culture agglutination

Preparation of spermatoZoa. Human spermatoZoa Were

Washed in TEST buffer (1/1 ratio), centrifuged (50,000><g)

medium containing peptides produced by papain appeared to
faster than the skim milk that contained the cultures that
Were groWn in the media containing the ?cin and bromelain

MW cut off polysulfone ultra?ltration membrane. Permeate
from the membrane Was freeZe dried to concentrate the

skim milk that contained the added immunoglobulin.
All three skim milk’s that Were inoculated With culture
groWn in media that contained peptides developed acid in
the top of the skim milk column faster (p<0.001) than the
peptides did not drop the initial pH of the skim milk as much
as the control media. Evidently peptides derived from blood
serum protected the culture from agglutinating and more of
the culture remained in solution. Culture groWn in the

Materials and Methods

Preparation of peptide blockers. Peptide blockers Were
prepared from sWeet Whey Which had been hydrolyZed With
papain at 28° C. During the hydrolyZation process peptides
Were collected by pumping the hydrolysate through a 10,000

ing in solution. The skim milk containing the other control
culture Was the second sloWest in developing acid in the top
of the cylinder. Evidently, suf?cient immune proteins Were
present in the skim milk to cause the culture to agglutinate
and drop to the bottom of the cylinder. HoWever, not as
many culture cells dropped in this skim milk as did in the

proteins form bridges betWeen sperm cells causing the cells

to agglutinate. Agglutination inhibits spermatoZoa mobility,

to the bottom of the cylinder. Since most of the culture Was

Insure
Insure + Immunoglobulin
Insure salt + Ficin peptide

attacks the spermatoZoa. The Immuno-proteins bind to anti
genic sites located on the surface of the sperm cell. These

immuno-proteins also bind to each other (complimentary
binding). As the immuno-proteins bind to antigenic sites on

RESULTS

Culture Medium

EXAMPLE 10

technician using a scale of 1 to 4.
Results and Discussion

Agglutination model. The model used to determine agglu
tination of human sperm cells Was designed to cause the

US 6,348,346 B1
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spermatozoa to agglutinate Within a short time interval
(approximately 10 min). This model Was considered to be an

tides and lactose (anhydrous). Peptides Were separated from

papain hydrolyZed Whey by ultra?ltration (10,000 mWco
polysulfone membrane) and freeZe dried. Empty aluminum

extremely harsh environment for normal sperm cells. Typi
cally sperm cells Would not encounter this concentration of

reference and sample pans Were paired to 10.5 mg. Samples

immuno-protein or blood serum. Also this model used a

Were Weighted (1.7 mg IgG, 4 mg peptide, 0.4 mg lactose)

different sperm donor each day, therefore the variability

in the sample pan and skim milk ultra?ltrate buffer Was

betWeen sperm sources to agglutination Was considered to

added by micro-pipette (to 100 pL volume). Samples Were

be maximiZed.
Free spermatoZoa. More free cells of spermatoZoa Were

dissolved by stirring With a micro-spatula. Sample and

observed (P<0.05) in samples containing peptide blockers

10

than samples Which did not contain peptide blockers (FIG.
6). Both blocked and unblocked spermatoZoa reaction mix
tures started out With approximately 400><105 free sWim

Thermal analysis of IgG revealed major heat ?oWs fol
loWed non-reversing heat ?oWs by approximately 1° C. at

ming cells. Free sWimming cells decrease (P<0.0001) With
time in both blocked and unblocked reactions. The reaction

15

mixture containing peptide blockers averaged 300><105 free
cells, While the sample Without peptide blockers averaged
200><105 free sWimming cells, a difference of nearly 100><
105 cells/ml. After incubating the reaction mixtures for 10
minutes, sperm cell agglutination abated and little neW
sperm cell agglutination occurred When reaction mixtures
contained 0.5 ml of blood serum. Sperm cell differentials
betWeen blocked and unblocked reaction mixtures betWeen

25

Zoa mobility Were conducted in reaction S mixtures con

30

TABLE 3

0

1

5

10

15

peaked at 46.0 and 51.8, respectively, and 87.9 and 942° C.,
respectively. These heat ?oWs appeared to align With tWo
minor heat ?oW areas observed in IgG but not With the major
heat ?oW area. Although modulated differential scanning
calorimetry cannot be used to identify a parent molecule it
can be used to identify disul?de bonds and structural char
acteristics that are apparent in both molecules. This data is
consistent and supports the observations that the active Whey
peptide are derived from immue proteins such as IgG.
In summary, numerous bene?ts have been described

Time (min)
TRTS

curves that did not appear to interfere With thermal analysis

of the peptide fraction. Fractionated Whey peptides con
tained 2 sulfur linkages that broke at peaks of 119 to 124°
C. Other heat ?oW patterns from Whey peptides started and

taining both 0.4 and 0.5 ml of blood serum. Results pre

sented in FIG. 3, shoW that reaction mixtures containing
peptide blockers had a greater mobility than those Without
blockers.

peaks of 74, 104 and 119 to 123° C. Aheat capacity shift Was
noted at 104° C. Minor non-reversing heat ?oWs occurred at
48 to 49, 54 to 55 and 88 to 90° C.
The freeZe dried fraction contained both lactose and

peptides. Lactose produced extremely linear heat ?oW
20

10 and 20 min averaged 70><105 cell/ml.

SpermatoZoa mobility. Experiments observing spermato

reference (empty) pans Were hermetically sealed. Calorim
etry measurements Were conducted (30 to 150° C.) With
modulation amplitude of 0.531° C./100 sec and ramp gra
dient of 2° C./min.
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40

50
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Which result from employing the concepts of the present
invention. A novel method has been described that is par

ticularly useful in inhibiting the binding activity of immu
noglobulins for a particular immunogen. Speci?cally, the

Motility
(‘70)

immunogen is treated With the inhibitor so as to block
W/PB
W/O

58
50

58
48

58
48

50
37

57
40

51
10

50
5

50
5

50
5

PB
Control

70

70

70

70

70

70

70

70

70

40

Grade

(0—4)
W/PB
W/O
PB
Control

antigenic sites or determinants that otherWise Would be the

target of immunoglobulin binding activity. Such a method
ology has a number of applications and is useful in virtually
all instances Where problematic immune reactions Would
otherWise occur. Such applications include but are not

3.5
3.3

3.5
3.3

3.5
3.3

3.3
3.0

3.3
3.0

3.3
0

3.3
0

3.2
0

3.0
0

3.5

3.5

3.5

3.5

3.5

3.5

3.5

3.5

3.5
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limited to improving the ef?ciency and effectiveness of the
cheese making process and arti?cial insemination tech

niques While protecting the spermatoZoa from host antibody

The results obtained in this study indicate that the pres
ence of peptides blockers reduced the incidence of aggluti
nation and higher numbers of “free” spermatoZoa exhibited

attack.
The invention has been described herein With reference to
50

HoWever, as it is obvious that variations thereon Will become
apparent to those skilled in the art, the invention is not to be

levels of motility and grade of motility (P<0.05). Signi?cant
agglutination occurred after 10 minutes of incubation.
Conclusions: SpermatoZoa incubated With TEST media in
the presence of peptide blockers Were immunoprotected
from the immune proteins present in bovine blood serum.
The qualative characteristics of these spermatoZoa suggest
that peptide blockers can be a useful mode of immunopro
tecting spermatoZoa during semen preparation and more

importantly after the placement of the spermatoZoa inside
the female reproductive tract.
EXAMPLE 11

Modulated differential scanning calorimetry (TA
instruments, Model DSC 2920) Was performed to thermally

analyZe Bovine IgG (reagent grade), hydrolyZed Whey pep

certain preferred methods and binding activity inhibitors.
considered as limited thereto.
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What is claimed is:
1. A method for inhibiting culture agglutination in a

fermentation medium including immunoglobulins, compris
ing the steps of:
contacting an immunoglobulin selected from the group

consisting of IgA, IgG, IgM and mixtures thereof With
a plant protease selected from the group consisting of
papain, ?cin, bromelain and mixtures thereof to hydro

lyZe the immunoglobulin, thereby forming a composi
tion comprised of immunoreactive peptides;

submitting the composition comprising immunoreactive
peptides to ultra?ltration and recovering and collecting
immunoreactive peptides having a molecular Weight of
less than 10,000 Daltons;
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lyZe the immunoglobulin, thereby forming a composi
tion comprised of immunoreactive peptides;
submitting the composition comprising immunoreactive

adding to a nutrient growth medium for a Lactococcus
useful in a fermentation process an amount of the

collected immunoreactive peptides of a molecular
Weight of less than 10,000 Daltons effective to bind
antigenic sites on the Lactococcus;
innoculating said nutrient groWth medium With the Lac

peptides to dia?ltration and recovering and collecting
immunoreactive peptides having a molecular Weight of
less than 10,000 Daltons;

tococcus useful in a fermentation process and groWing

adding to a nutrient groWth medium for a Lactococcus

said Lactococcus in the nutrient groWth medium until

useful in a fermentation process an amount of the

antigenic sites on the Lactococcus are bound and
blocked With immunoreactive peptides of a molecular

10

Weight of less than 10,000 Daltons;

transferring the proliferated Lactococcus having antigenic

a fermentation process and groWing said Lactococcus
in the nutrient groWth medium until antigenic sites on

sites blocked to a fermentation medium Wherein immu

noglobulins comprised in the fermentation medium
cannot bind the antigenic sites on the Lactococcus

15

blocked by immunoreactive peptides of a molecular

sites blocked to a fermentation medium Wherein immu
20

group consisting of raW Whey, dried Whey, Whey protein
isolates, non-fat-dried milk, blood serum protein isolates,
puri?ed immune protein preparations and mixtures thereof.

cannot bind the antigenic sites on the Lactococcus

Weight of less than 10,000 Daltons;
Whereby agglutination of the Lactococcus in the fermen
25

ing the steps of:
contacting an immunoglobulin selected from the group

consisting of IgA, lgG, IgM and miXtures thereof With
a plant protease selected from the group consisting of
papain, ?cin, bromelain and mixtures thereof to hydro

tation medium is inhibited.
5. The method as set forth in claim 4, including adding a

buffer to the composition comprising immunoreactive pep
tides at the same rate as the immunoreactive peptides are

4. A method for inhibiting culture agglutination in a

fermentation medium including immunoglobulins, compris

noglobulins comprised in the fermentation medium
blocked by immunoreactive peptides of a molecular

1,000 Daltons.
3. The method set forth in claim 1, Wherein said immu
noglobulin is provided from a source selected from the

the Lactococcus are bound and blocked With immu

noreactive peptides of a molecular Weight of less than

10,000 Daltons;
transferring the proliferated Lactococcus having antigenic

Weight of less than 10,000 Daltons;
Whereby agglutination of the Lactococcus in the fermen
tation medium is inhibited.
2. The method as set forth in claim 1, Wherein said
immunoreactive peptides have a molecular Weight of about

collected immunoreactive peptides of a molecular
Weight of less than 10,000 Daltons effective to bind
antigenic sites on the Lactococcus; innoculating said
nutrient groWth medium With the Lactococcus useful in

30

collected.
6. The method as set forth in claim 4, Wherein the
immunoglobulin is contacted With the plant protease at a
temperature betWeen 30—50° C. for a period of time of at
least tWo hours.

